AmMax's innovative and highly differentiated oncology portfolio includes the novel next generation ADC for the treatment of multiple cancers by targeting a tumor-associated antigen overexpressed across a broad range of solid tumors. The program has a robust data package that supports a significantly widened therapeutic index and predicts a much-improved efficacy and safety profile..
The AmMax team has established a solid track record of advancing its program development, including the completion of multiple clinical studies that produced positive proof-of-concept data for its second program for the treatment of tenosynovial giant cell tumor (TGCT). Developed as a “local administration for a local disease” the program has the potential to bring significant clinical benefits to a much broader set of TGCT patients.
With a seasoned management team and a robust pipeline, AmMax is poised to grow into a leading oncology company.
Launched in March 2020 to develop innovative therapeutics with a focus on oncology, AmMax Bio, Inc. (“AmMax”) is a clinical stage company successfully leveraging its expertise in translational and clinical development to build a strong oncology portfolio focused on sizeable market opportunities via licensing and partnerships. The Company’s portfolio, anchored by a novel next generation antibody-drug conjugate (ADC), has the potential to create new standards of care.
AmMax has a very experienced management team, led by Dr. Larry Hsu, co-founder and former CEO of Impax Laboratories, Inc., which he successfully built into a fully integrated multi-billion dollar publicly traded pharmaceutical company. With broad experience across therapeutic areas and therapeutic modalities, the AmMax team is strong in execution and has collectively brought multiple BLAs, NDAs and MAAs to approval and commercialization.